

Special Issue

New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges

Message from the Guest Editor

Remarkable research efforts have been made in lowering plasma cholesterol levels by the widespread use of statins resulting in significant reduction of death rate by ~30%–40%. Despite all these efforts, cardiovascular disease (CVD) continue to be the leading cause of mortality worldwide. After recent failure with cholesteryl ester transfer protein inhibitors, effective lipid lowering drugs emerged as new revolutionizing lipid-lowering therapy. In this context, human anti-PCSK9 antibodies have been shown in a wide range of patients, including those with statins intolerance, to significantly decrease plasma cholesterol by ~50%–70% with no alarming safety signals.

This Special Issue will provide an open access opportunity to publish research work and review articles related to recent advances in the field of CVD, new molecular insights and potential therapeutic strategies for better patient diagnosis and disease prevention.

Guest Editor

Dr. Ahmed Bakillah

King Abdullah International Medical Center (KAIMRC), Eastern Region,
King Saud Bin Abdul-Aziz University of Health Sciences, Ministry of
National Guards- Health Affairs, Mail Code 520, PO. Box 6664, AL Asha
31982, Saudi Arabia

Deadline for manuscript submissions

closed (31 December 2018)



Diseases

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/10175

Diseases
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diseases@mdpi.com

[mdpi.com/journal/
diseases](https://mdpi.com/journal/diseases)





Diseases

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
diseases](https://mdpi.com/journal/diseases)



About the Journal

Message from the Editorial Board

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

Diseases is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Editors-in-Chief

Prof. Dr. Maurizio Battino

Department of Odontostomatologic and Specialized Clinical Sciences,
Sez-Biochimica, Faculty of Medicine, Università Politecnica delle
Marche, Via Ranieri 65, 60100 Ancona, Italy

Prof. Dr. Omar Cauli

Frailty and Cognitive Impairment—FROG Research Group, University of
Valencia, 46010 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.